Investment Thesis
Anebulo Pharmaceuticals is a pre-revenue pharmaceutical company with significant ongoing losses and negative cash flow, indicating it is in early-stage development without commercial operations. The company's financial viability depends entirely on successful drug development and future revenue generation, with current burn rate consuming approximately 29% of cash reserves annually.
Strengths
- Strong liquidity position with $9.0M cash representing 95.7% of total assets
- Minimal debt burden with zero long-term debt and low liabilities ($1.5M)
- Excellent current/quick ratios (31.63x) providing substantial runway for operations
Risks
- No revenue generation indicating company has not achieved commercialization of any products
- Persistent operating losses of $4.9M with negative net income of $4.2M
- Negative free cash flow of $2.6M annually creating material runway depletion risk; at current burn rate, cash reserves depleted in approximately 3.5 years without additional funding
- Extreme negative ROE (-52.4%) and ROA (-44.1%) demonstrating value destruction
- Zero insider transactions in last 90 days suggesting lack of management confidence or activity
- High execution risk inherent to pharmaceutical development stage companies with binary outcomes
Key Metrics to Watch
- Operating cash burn rate and cash runway duration
- Clinical trial progress and regulatory milestones for pipeline programs
- Equity financing activities and capital raise announcements
- Path to revenue generation and product commercialization timeline
- Changes in insider ownership and executive compensation structure
Financial Metrics
Revenue
N/A
Net Income
-4.2M
EPS (Diluted)
$-0.10
Free Cash Flow
-2.6M
Total Assets
9.4M
Cash
9.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-52.4%
ROA
-44.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
31.63x
Quick Ratio
31.63x
Debt/Equity
0.00x
Debt/Assets
15.8%
Interest Coverage
-139.43x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:13:30.803622 |
Data as of: 2025-12-31 |
Powered by Claude AI